Market Overview

Goldman Sachs Downgrades Aetna To Neutral

Share:
Related AET
Benzinga's Top Upgrades
UBS Has Had Enough: Centene Upgraded To Buy On 'Underappreciated Opportunities'
Notable earnings before Tuesday's open (Seeking Alpha)

Analysts at Goldman Sachs downgraded Aetna (NYSE: AET) from Buy to Neutral.

The target price for Aetna has been lowered from $94.00 to $88.00.

Aetna shares have surged 24.00% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.

Aetna's shares dropped 0.61% to $77.84 in pre-market trading.

Latest Ratings for AET

DateFirmActionFromTo
Jul 2015Bank of AmericaUpgradesNeutralBuy
Jul 2015FBR CapitalDowngradesOutperformMarket Perform
Jul 2015BarclaysMaintainsOverweight

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Goldman SachsDowngrades Analyst Ratings

 

Related Articles (AET)

Get Benzinga's Newsletters